Blueprint Medicines

Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases, blood disorders, and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Blueprint Medicines exceeds revenue expectations, eyes growth opportunities in 2023

Blueprint Medicines delivered strong financial results and outlined growth strategies for 2023, driven by AYVAKIT's performance.
The company faces uncertainties around label negotiation but benefits from strong market access and proactive market expansion efforts.
Opportunities lie in upcoming data presentations, CDK2 program updates, and capturing additional market share in the ISM segment.

Blueprint Medicines reports strong Q1 performance and growth opportunities

Blueprint Medicines showcased strong financial performance, a robust growth strategy, and promising pipeline advancements during the Q1 earnings call. While facing challenges in managing expenses and differentiating sales, the company is well-positioned to capitalize on opportunities in driving AYVAKYT sales and educating providers on SM treatment urgency.

Blueprint Medicines reports strong Q2 results and eyes market expansion

Blueprint Medicines demonstrated solid financial performance and positive market reception for AYVAKIT and BLU-222.
While facing challenges in operational execution and market competition, the company has opportunities for growth through portfolio expansion and market diversification.
Overall, Blueprint Medicines is well-positioned to capitalize on the success of AYVAKIT and the potential of BLU-222 in driving future growth and innovation.

Blueprint Medicines excels in Q3, eyes sustainable growth in 2024

Blueprint Medicines delivered strong Q3 results with a focus on sustainable revenue growth and pipeline advancement.
The company's strengths lie in AYVAKIT's market adoption, high patient retention rates, and promising pipeline assets.
Challenges include managing operating expenses, decreasing cash burn, and expanding market penetration for AYVAKIT.
Opportunities exist in developing new assets, presenting upcoming data, and achieving significant growth in 2024.

Blueprint Medicines reports robust 2023 performance and targets $2B peak sales

Blueprint Medicines' strong 2023 performance with AYVAKIT driving revenue growth sets the stage for continued success in 2024, aiming for peak sales exceeding $2 billion.
Strategic focus on expanding market presence, advancing pipeline assets, and maintaining financial discipline positions the company for sustained growth and profitability.
Opportunities lie in maximizing AYVAKIT's market potential, leveraging BLU-808 in inflammatory disorders, and exploring strategic growth avenues in cancer treatment.

Blueprint Medicines reports robust Q1 earnings, eyes strategic partnerships

Blueprint Medicines' strong financial performance, focus on sustainable growth, and strategic expansion into new therapeutic areas position the company for long-term success. Addressing challenges in physician adoption and patient prescription rates while leveraging growth opportunities in strategic partnerships and compound expansion will be crucial for future growth.

Blueprint Medicines excels in Q3 with robust AYVAKIT sales

Blueprint Medicines delivered strong revenue growth driven by AYVAKIT sales, showcasing high compliance and demand. With a focus on long-term growth and financial stability, the company aims to expand its impact with BLU-808 and maintain strong capital allocation priorities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass. , Jan. 6, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of John Tsai, M.D.

Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors

-- Expect to achieve high-end of 2022 total revenue guidance of $180 million to $200 million and AYVAKIT product revenue guidance of $108 million to $111 million -- -- Positioned for significant near-term growth with potential FDA approval of AYVAKIT® (avapritinib) in indolent systemic mastocytosis in the middle of 2023 -- -- Anticipate multiple clinical data catalysts across mast cell disorder, EGFR-mutant non-small cell lung cancer, and breast cancer programs in 2023 -- -- Kate Haviland, Chief Executive Officer, to present company overview and 2023 outlook at 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10 at 4:30 p.m.

Blueprint Medicines Provides 2023 Portfolio Goals to Achieve Precision at Scale

Blueprint Medicines Corporation has multiple approved drugs and potential label expansions. Sales have not been as good as expected.

Blueprint Medicines: A Slow But Steady Blueprint For Success

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock?

Blueprint Medicines (BPMC) Up 3.7% Since Last Earnings Report: Can It Continue?

Blueprint Medicines (BPMC) submits a supplemental new drug application for its lead drug, Ayvakit, for the treatment of indolent systemic mastocytosis to the FDA.

Blueprint Medicines (BPMC) Files Ayvakit sNDA for Indolent SM

-- Company to present registrational PIONEER trial results at 2023 AAAAI Annual Meeting -- CAMBRIDGE, Mass. , Nov. 22, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the submission of a supplemental new drug application to the U.S. Food and Drug Administration (FDA) for AYVAKIT® (avapritinib) for the treatment of adults with indolent systemic mastocytosis (SM).

Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (avapritinib) for the Treatment of Indolent Systemic Mastocytosis

CAMBRIDGE, Mass. , Nov. 3, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the acceptance of abstracts highlighting long-term clinical outcomes and impact on overall survival of AYVAKIT® (avapritinib) in patients with advanced systemic mastocytosis (SM), as well as real-world evidence characterizing the burden of SM, for presentation at the 2022 American Society of Hematology (ASH) Annual Meeting in December.

Blueprint Medicines to Present New Data Reinforcing Clinical Leadership in Systemic Mastocytosis at 2022 ASH Annual Meeting

Blueprint Medicines' (BPMC) earnings and revenues trump estimates for the third quarter of 2022. The company lowers product revenue guidance for Ayvakit.

Blueprint Medicines (BPMC) Q3 Earnings & Revenues Top Mark

-- On track to submit supplemental new drug application for AYVAKIT® (avapritinib) in non-advanced SM in Q4 2022, with an anticipated U.S. launch in mid-2023 -- -- Reports updated data from the SYMPHONY trial of BLU-945 demonstrating clinical activity and a differentiated safety profile, supporting combination development in first-line EGFR-mutant non-small cell lung cancer -- -- Expects to achieve the high-end of total revenue guidance of $180 million to $200 million for full-year 2022 -- -- Blueprint Medicines to webcast Investor Day 2022 event today at 8:30 a.m. ET -- CAMBRIDGE, Mass.

Blueprint Medicines Outlines 2027 Blueprint to Achieve Precision Medicine at Scale and Reports Third Quarter 2022 Financial Results at Investor Day 2022

CAMBRIDGE, Mass. , Oct. 19, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host an Investor Day for analysts and investors on Tuesday, November 1, 2022 beginning at 8:30 a.m.

Blueprint Medicines to Host Investor Day and Announce Third Quarter 2022 Financial Results on November 1, 2022

Blueprint Medicines (BPMC) expects its lead drug, Ayvakit, which is approved to treat rare cancer and other rare diseases, to generate incremental sales and combat stiff competition.

Will Ayvakit Aid Blueprint Medicines (BPMC) Amid Rivalry?

Blueprint has a few recently approved therapies, and has recently sold royalties for over $1 billion. While this limits revenue potential now, the profits can be leveraged back into advancing the pipeline.

Blueprint Medicines: Royalties Being Sold Allows For More Shots On Goal

Blueprint Medicines' (BPMC) Ayvakit, approved for treating PDGFRA Exon 18 mutant gastrointestinal stromal tumors, is witnessing strong uptake. The drug's label expansion studies also hold promise.

Blueprint Medicines (BPMC) Rises 68.2% in 3 Months: Here's Why

New York, New York--(Newsfile Corp. - September 3, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Blueprint Medicines Corporation (NASDAQ: BPMC) resulting from allegations that Blueprint Medicines may have issued materially misleading business information to the investing public.

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Blueprint Medicines Corporation Investors to Inquire About Class Action Investigation - BPMC

Blueprint Medicines (BPMC) Up 22.7% Since Last Earnings Report: Can It Continue?

NEW YORK , Aug. 29, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Blueprint Medicines Corporation (NASDAQ: BPMC) resulting from allegations that Blueprint Medicines may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Blueprint Medicines securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Blueprint Medicines Corporation Investors to Inquire About Class Action Investigation - BPMC

Los Angeles, California--(Newsfile Corp. - August 24, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ: BPMC) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm

-- Patients across the spectrum of disease reported substantial symptom burden, as well as scores of physical functioning and mental health that are worse than historical data for patients with colorectal or lung cancer -- CAMBRIDGE, Mass. , Aug. 24, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced two publications in the medical journal CANCER describing results from the TouchStone patient and healthcare provider (HCP) study designed to characterize the burden and needs of patients living with systemic mastocytosis (SM).

CANCER Publishes Study Demonstrating Substantial Disease Burden for Patients with Systemic Mastocytosis

Los Angeles, California--(Newsfile Corp. - August 23, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ: BPMC) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - August 22, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ: BPMC) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - August 19, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ: BPMC) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm

Blueprint Medicines (BPMC) posts top-line data from part 2 of the PIONEER study evaluating Ayvakit in patients with non-advanced systemic mastocytosis. Shares down.

Blueprint Medicines' (BPMC) Ayvakit Meets Goal in PIONEER Study

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Blueprint Medicines Corporation (NASDAQ: BPMC) resulting from allegations that Blueprint Medicines may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Blueprint Medicines securities you may be entitled to compensation without payment of any out of pocket fees or costs th

EQUITY ALERT: Rosen Law Firm Encourages Blueprint Medicines Corporation Investors to Inquire About Class Action Investigation – BPMC

Blueprint Medicines Corp (NASDAQ: BPMC) shares are trading lower by 22.2% to $53.32 Wednesday morning after the company announced top-line results from the registrational Part 2 of the PIONEER clinical trial of AYVAKIT in patients with non-advanced systemic mastocytosis.

Here's Why Blueprint Medicines Stock Is Falling

Blueprint unveiled the "long-awaited" results of its study in indolent systemic mastocytosis on Wednesday, and the biotech stock crashed. The post Blueprint Medicines Stock Hammered As 'Long-Awaited' Test Results Disappoint appeared first on Investor's Business Daily.

News for Blueprint Medicines Stock (BPMC)